131466-61-0

Basic information

• Product Name: (3R)-3-(tert-ButyldiMethylsilyloxy)glutaric acid -1-((R)-(-)-Mandelic acid ester
• Synonyms: (3R)-3-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]pentanedioic acid 1-[(R)-carboxyphenylmethyl] ester;(3R)-3-(tert-ButyldiMethylsilyloxy)glutaric acid -1-((R)-(-)-Mandelic acid ester
• CAS NO: 131466-61-0
• Molecular Formula: C₁₉H₂₈O₇Si
• Molecular Weight: 396.50692
• Mol File: 131466-61-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3R)-3-(tert-ButyldiMethylsilyloxy)glutaric acid -1-((R)-(-)-Mandelic acid ester(CAS DataBase Reference)
• NIST Chemistry Reference: (3R)-3-(tert-ButyldiMethylsilyloxy)glutaric acid -1-((R)-(-)-Mandelic acid ester(131466-61-0)
• EPA Substance Registry System: (3R)-3-(tert-ButyldiMethylsilyloxy)glutaric acid -1-((R)-(-)-Mandelic acid ester(131466-61-0)

Safety Data

• Hazardous Substances Data: 131466-61-0(Hazardous Substances Data)

Usage

General Description

The chemical compound "(3R)-3-(tert-Butyldimethylsilyloxy)glutaric acid -1-((R)-(-)-mandelic acid ester" is a complex molecule with multiple functional groups. It consists of a (3R)-3-(tert-butyldimethylsilyloxy)glutaric acid moiety and a (R)-(-)-mandelic acid ester moiety. The (3R)-3-(tert-butyldimethylsilyloxy)glutaric acid group contains a carboxylic acid and a tert-butyldimethylsilyloxy functional group, while the (R)-(-)-mandelic acid ester contains an ester functional group. These functional groups give the compound its unique properties and potential applications in organic synthesis and medicinal chemistry.

Upstream product

• 10606-72-1 (R)-mandelic acid ethyl ester 
• 91424-40-7 3-(tert-butyldimethylsilyloxy)glutaric anhydride 
• 97415-09-3 (R)-benzyl 2-hydroxy-2-phenyl-acetate 
• 32328-03-3 diethyl 3-hydroxyglutarate 
• 91424-39-4 3-[[(1,1-Dimethylethyl)dimethylsilyl]-oxy]pentanedioic acid,diethyl ester 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 147118-35-2 methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate 
• 147118-39-6 methyl (3R,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3-hydroxy-5-oxohept-6-enoate 
• 1350364-05-4 hydrogen (3R)-1-methyl 3-[(tert-butyldimethylsilyl)-oxy]pentanedioate benzylamine salt 
• 1350364-18-9 C₁₅H₂₈O₇Si 
• 182075-76-9 (R,E)-methyl 3-(tert-butyldimethylsilyloxy)-7-(2-cyclopropyl-4-(-4-fluorophenyl)-quinolin-3-yl)-5-oxohept-6-enoate 
• 917752-45-5 methyl (E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3-quinolinyl]-3-hydroxy-5-oxo-6-heptenate 
• 109744-49-2 Hydrogen (3R)-1-methyl 3-<(tert-butyldimethylsilyl)oxy>pentanedioate 

Relevant articles and documents

Preparation method of high-purity statin drug intermediate

The invention relates to a preparation method of a high-purity statin drug intermediate. The preparation method is characterized in that 3-hydroxyl ethyl glutarate is used as the initial raw material to prepare (3R)-tert-butyl dimethyl silyloxy-5-oxo-6-triphenyl phosphine caproate (abbreviated as J6) through substitution reaction, hydrolysis reaction, cyclization reaction, resolution reaction, hydrogenation reaction, acylation reaction and Wittig reaction. The preparation method is mild in condition, stable in process, cheap in raw material, easy in raw material obtaining, easy in three-waste treatment, low in preparation cost, high in product purity and suitable for industrial production.

AN IMPROVED PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF HMG-COA REDUCTASE INHIBITORS

The present invention relates to an improved process for the preparation of intermediates of HMG-CoA reductase inhibitors of Formulae-IXa or IXb and further conversion to HMG-CoA reductase inhibitors and pharmaceutically acceptable salts thereof.